title: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.
abstract: BACKGROUND
  There are only limited data on human immunodeficiency virus type 1 (HIV-1) RNA in perinatally infected infants. Understanding the dynamics of HIV-1 infection and its relation to disease progression may help identify opportunities for effective antiviral treatment in infected infants.
  
  
  METHODS
  We obtained plasma samples from 106 HIV-infected infants at birth; at 1, 2, 4, 6, 9, 12, 15, and 18 months of age; and subsequently every 6 months. HIV-1 RNA was assayed by means of a reverse-transcription polymerase chain reaction. The infants were born between 1990 and 1993, and only 21 percent of the infants' mothers received any treatment with zidovudine during pregnancy.
  
  
  RESULTS
  Plasma HIV-1 RNA levels increased rapidly after birth, peaked at 1 to 2 months of age (median values at 1 and 2 months, 318,000 and 256,000 copies per milliliter, respectively), and then slowly declined to a median of 34,000 copies per milliliter at 24 months. Newborns with a first positive HIV-1 culture within 48 hours after birth had significantly higher HIV-1 RNA levels, although only during the first two months of life, than those with a first positive culture seven or more days after birth. Infants with a rapid progression of disease had higher peak HIV-1 RNA levels in the first two months of life than those without rapid progression (median value, 724,000 vs. 219,000 copies per milliliter; P=0.006), as well as a higher geometric mean value during the first year of life (median value, 330,000 vs. 158,000 copies per milliliter, P=0.001).
  
  
  CONCLUSIONS
  In perinatally infected infants, HIV-1 RNA levels are high and decline only slowly during the first two years of life. Infants with very high viral loads in the first months of life are at increased risk for a rapid progression of disease, which suggests that early treatment with antiretroviral agents may be indicated for these infants.
authors.affiliation: Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
authors.forename: W T
authors.initials: WT
authors.lastname: Shearer
authors.forename: T C
authors.initials: TC
authors.lastname: Quinn
authors.forename: P
authors.initials: P
authors.lastname: LaRussa
authors.forename: J F
authors.initials: JF
authors.lastname: Lew
authors.forename: L
authors.initials: L
authors.lastname: Mofenson
authors.forename: S
authors.initials: S
authors.lastname: Almy
authors.forename: K
authors.initials: K
authors.lastname: Rich
authors.forename: E
authors.initials: E
authors.lastname: Handelsman
authors.forename: C
authors.initials: C
authors.lastname: Diaz
authors.forename: M
authors.initials: M
authors.lastname: Pagano
authors.forename: V
authors.initials: V
authors.lastname: Smeriglio
authors.forename: L A
authors.initials: LA
authors.lastname: Kalish
mesh_terms: D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000635:transmission / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008137:Longitudinal Studies; D008297:Male; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D012367:RNA, Viral